$0.20
−13.04%Price chart
Jul 24Aug 3Aug 13Aug 20Aug 25Aug 31Sep 3Sep 14
Key dataSep 14, 2026
Open$2.10
From 52W high−95.24%
Volume16501.00
Market cap$10.22M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 14, 2026
Open
$2.10
From 52W high
−95.24%
Volume
16501.00
Market cap
$10.22M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.7x
P/E (TTM)
—
RSI (14)
46.0
MomentumView details →
1D Return
−13.04%
YTD Return
−93.24%
SummaryUpdated Jul 1, 2026
enGene Holdings Inc. (NASDAQ:ENGNW) is a clinical-stage biotechnology company founded in 2023 and headquartered in Saint-Laurent, Canada. The company operates through its subsidiary enGene, Inc., and focuses on developing genetic medicines delivered to mucosal tissues and other organs. As a recently established biotech firm, enGene is currently in the clinical development phase with no commercial revenue, dedicating its resources to advancing its lead therapeutic candidate through regulatory trials for cancer treatment.
Similar companies
Latest newsMore news →
enGene Therapeutics Inc. reported its Q3 2026 financial results, with a net loss of $32.5 million and diluted EPS of -$0.47, and cash and marketable securities of $266.3 million.12d agoRichard Glickman resigned as director and chairman of the Board of Directors of enGene Therapeutics Inc., effective July 15, 2026.67d ago